Q2

Eclipse Labs Announces $50M Series A Funding co-led by Placeholder and Hack VC

Retrieved on: 
Tuesday, March 12, 2024
Professional Services, Blockchain, NFT, Apps, Applications, Technology, Cryptocurrency, Software, Citadel, Developer, Uniswap, EVM, Environment, Discord, SVM, L2, Lead, Polychain Capital, Q2, Testnet, Engineering, Flow Traders, DBA, Marketing, Celestia, Architecture, Auros, Ecosystem, GSR, San Francisco Bay Area, Apollo Global Management

Eclipse Labs , a software firm contributing to the development of the first Ethereum layer-2 using the Solana Virtual Machine (SVM), has raised $50M of Series A funding co-led by Placeholder and Hack VC, bringing the total capital raised to $65M.

Key Points: 
  • Eclipse Labs , a software firm contributing to the development of the first Ethereum layer-2 using the Solana Virtual Machine (SVM), has raised $50M of Series A funding co-led by Placeholder and Hack VC, bringing the total capital raised to $65M.
  • "Eclipse is built to be Ethereum's fastest layer-2, leveraging the best pieces of the modular stack available today," said Neel Somani, Founder of Eclipse Labs.
  • Eclipse integrates the high-performance SVM with the deep pools of liquidity on Ethereum, while maintaining the hard constraint of verifiability."
  • Eclipse Labs intends on sponsoring hackathons and accelerators, in addition to community-building events targeted toward users who interact with Eclipse Mainnet.

Dun & Bradstreet: Global Business Optimism Continues to Climb as Businesses Indicate Sustained Confidence

Retrieved on: 
Wednesday, April 3, 2024
Dun & Bradstreet, Disaster, ESG, Dun, Policy, Q2, Overalls, Investment, Optimism, Weather, Retail

LONDON, April 3, 2024 /PRNewswire/ -- Dun & Bradstreet (NYSE:DNB), a leading global provider of business decisioning data and analytics, today released its Q2 2024 Global Business Optimism Insights report. The latest quarterly report highlights a sustained positive trend in the global business outlook, with the Dun & Bradstreet Global Business Optimism Index rising 5.4% quarter over quarter.

Key Points: 
  • LONDON, April 3, 2024 /PRNewswire/ -- Dun & Bradstreet (NYSE:DNB), a leading global provider of business decisioning data and analytics, today released its Q2 2024 Global Business Optimism Insights report.
  • The latest quarterly report highlights a sustained positive trend in the global business outlook, with the Dun & Bradstreet Global Business Optimism Index rising 5.4% quarter over quarter.
  • "The continued improvement in overall business optimism indicates that businesses are regaining stability after grappling with inflationary pressures and global monetary tightening," said Neeraj Sahai, President of Dun & Bradstreet International.
  • Key findings from the Q2 report reveals:
    The Global Business Optimism Index increased 5.4%, with businesses feeling more optimistic about the global macroeconomic environment, particularly regarding inflation.

EudraVigilance registration manual

Retrieved on: 
Wednesday, April 3, 2024
Scroll, University, Data analysis, Patient, Account, Organization, MAH, Medicine, Manual, MFL, IAM, VAT, Finalize (optical discs), QAT, Competence, Documentation, Letter, Privacy, HQ2, ServiceNow, Environment, Trust (social science), RP, Table, Record, MPR, European Medicines Agency, Restricted area, Yahoo!, Identity management, Change request, Access, Qualified person (European Union), HQ, MMD, Home, Hospital, Research, Service, Network affiliate, Comment, Access management, OMS, Send, MSSO, ISO, Commercial, European, NCA, NCS, Managed services, Next, Document, EMA, PSMF, Language, MedDRA, AMP, Database, ICSR, Figure, EudraGMP, Dictionary, AMPS, Reproduction, Quality assurance, Identity, Virtual, Q2, SME, Change, Importance, Management, Security, Name, Location, Sponsor, Completeness, ID, 24 Hours, User, Vaccine
Key Points: 

    Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

    Retrieved on: 
    Monday, March 11, 2024
    Therapy, SAN, Ulcerative colitis, Week, CDAI, B cell, Atopic dermatitis, BTLA, Q2, PD-1, Inflammation, Annual general meeting, AAD, UC, Idealized cognitive model, Rheumatoid arthritis, IGA, Patient, BDCA2, IND

    “We will have a number of important events in 2024 including the top-line data readout of ANB032's Phase 2b trial in atopic dermatitis by year end,” adds Faga. “We also plan to move our third and fourth ICMs -- ANB033, our anti-CD122 antagonist, and ANB101 -- into the clinic this year, with IND filings planned for Q2 and H2, respectively.”

    Key Points: 
    • “Enrollment is ongoing in three global Phase 2 trials for ANB032, our BTLA agonist, in atopic dermatitis and rosnilimab, our PD-1 agonist, in rheumatoid arthritis and ulcerative colitis.
    • The decrease relates primarily to cash used for operating activities and the $50 million stock repurchase program.
    • The change is due primarily to increased royalties recognized for sales of Jemperli offset by one development milestone achieved for cobolimab in 2022.
    • Acquired in-process research and development of $7.3 million for the three and twelve months ended December 31, 2023 related to the exclusive licensing agreement with Centessa Pharmaceuticals.

    Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results

    Retrieved on: 
    Tuesday, March 5, 2024
    Investment, FDA, Quality of life, Sensation, Growth, Q2, Mastectomy, Webcast, Nerve, Patient, Trauma, Internet, Video game

    Fourth quarter revenue was $42.9 million, an 18.7% increase compared to the fourth quarter of 2022.

    Key Points: 
    • Fourth quarter revenue was $42.9 million, an 18.7% increase compared to the fourth quarter of 2022.
    • The Company estimates that revenues from emergent trauma procedures represented approximately half of total revenues during the fourth quarter and grew mid-single digits versus the fourth quarter of 2022.
    • Gross margin was 78.7% for the fourth quarter compared to 83.0% in the fourth quarter of 2022.
    • Adjusted EBITDA was $0.6 million for the quarter, compared to an adjusted EBITDA loss of $0.7 million in the fourth quarter of 2022.

    Coupang Announces Results for Fourth Quarter 2023

    Retrieved on: 
    Tuesday, February 27, 2024
    Retail, Online Retail, Other Retail, Food, Beverage, International, FLC, WOW, Growth, Commerce, Q2, Yoy, EPS, FX, Aquaculture

    Coupang, Inc. (NYSE: CPNG) today announced financial results for its fourth quarter ended December 31, 2023.

    Key Points: 
    • Coupang, Inc. (NYSE: CPNG) today announced financial results for its fourth quarter ended December 31, 2023.
    • Adjusted EBITDA for the quarter was $294 million with a margin of 4.5%, an improvement of 50 bps over last year.
    • The accounting change in FLC revenue this quarter had a positive impact of 40 bps on margin.
    • “We are extremely proud of our teams whose work over many years is responsible for the results we reported throughout this year.

    Q2 Holdings, Inc. Announces Fourth Quarter and Full-Year 2023 Financial Results

    Retrieved on: 
    Wednesday, February 21, 2024
    Professional Services, Payments, Technology, Software, Finance, Fintech, Banking, Small business, Growth, Table, Q2, Adjustment, GAAP, Credit union, Net, Depreciation, Video game

    Revenue for the fourth quarter of $162.1 million, up 11 percent year-over-year and up 5 percent from the third quarter of 2023.

    Key Points: 
    • Revenue for the fourth quarter of $162.1 million, up 11 percent year-over-year and up 5 percent from the third quarter of 2023.
    • GAAP net loss for the fourth quarter of $18.1 million, compared to GAAP net losses of $32.4 million for the prior-year quarter and $23.2 million for the third quarter of 2023.
    • Non-GAAP revenue for the fourth quarter of $162.2 million, up 11 percent year-over-year and up 5 percent from the third quarter of 2023.
    • Adjusted EBITDA for the fourth quarter of $23.2 million, up from $8.4 million for the prior-year quarter and $19.7 million for the third quarter of 2023.

    Neonode Reports 2023 Financial Results

    Retrieved on: 
    Wednesday, February 28, 2024
    System, Marketing, Growth, NEON, Asset, TSM, FINANCIAL, Q2

    STOCKHOLM, Sweden, Feb. 28, 2024 /PRNewswire/ -- Neonode Inc. (NASDAQ: NEON) today reported financial results for the fiscal year ended December 31, 2023.

    Key Points: 
    • STOCKHOLM, Sweden, Feb. 28, 2024 /PRNewswire/ -- Neonode Inc. (NASDAQ: NEON) today reported financial results for the fiscal year ended December 31, 2023.
    • Cash and accounts receivable of $17.1 million as of December 31, 2023 compared to $16.3 million for the prior year-end.
    • FINANCIAL OVERVIEW FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023
      Net revenues for fiscal 2023 were $4.4 million, a 21.5% decrease compared to 2022.
    • Net loss attributable to Neonode for fiscal 2023 was $10.1 million, or $0.66 per share, compared to a net loss of $4.9 million, or $0.36 per share for 2022.

    Neonode Reports 2023 Financial Results

    Retrieved on: 
    Wednesday, February 28, 2024
    System, Marketing, Growth, NEON, Asset, TSM, FINANCIAL, Q2

    STOCKHOLM, Sweden, Feb. 28, 2024 /PRNewswire/ -- Neonode Inc. (NASDAQ: NEON) today reported financial results for the fiscal year ended December 31, 2023.

    Key Points: 
    • STOCKHOLM, Sweden, Feb. 28, 2024 /PRNewswire/ -- Neonode Inc. (NASDAQ: NEON) today reported financial results for the fiscal year ended December 31, 2023.
    • Cash and accounts receivable of $17.1 million as of December 31, 2023 compared to $16.3 million for the prior year-end.
    • FINANCIAL OVERVIEW FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023
      Net revenues for fiscal 2023 were $4.4 million, a 21.5% decrease compared to 2022.
    • Net loss attributable to Neonode for fiscal 2023 was $10.1 million, or $0.66 per share, compared to a net loss of $4.9 million, or $0.36 per share for 2022.

    iRobot Reports Fourth-Quarter and Full-Year 2023 Financial Results

    Retrieved on: 
    Monday, February 26, 2024
    Engineering, IRobot, Marketing, Q2, IRBT, Interim, Q3, GAAP, News, MSRP, Workforce, Research, Environment

    BEDFORD, Mass., Feb. 26, 2024  /PRNewswire/ -- iRobot Corp. (NASDAQ: IRBT), a leader in consumer robots, today announced its financial results for the fourth quarter and full year ended December 30, 2023.  

    Key Points: 
    • BEDFORD, Mass., Feb. 26, 2024 /PRNewswire/ -- iRobot Corp. (NASDAQ: IRBT), a leader in consumer robots, today announced its financial results for the fourth quarter and full year ended December 30, 2023.
    • Geographically, fourth quarter 2023 revenue declined 20% in the U.S., 19% in Japan and 5% in EMEA over the prior period last year.
    • iRobot is providing GAAP and non-GAAP financial expectations for the fiscal year ending December 28, 2024.
    • A detailed reconciliation between the Company's GAAP and non-GAAP expectations is included in the attached financial tables.